High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
This phase 3 GEM12 trial evaluated long-term outcomes of autologous stem cell transplantation (ASCT) conditioning with b...
Treatment of transplant-ineligible multiple myeloma.
- Post category:Hematologic Cancers
- Reading time:1 min read
This publication reviews the evolving treatment landscape for transplant-ineligible multiple myeloma (MM) patients. It h...
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).
- Post category:Hematologic Cancers
- Reading time:1 min read
This randomized study evaluated pomalidomide, cyclophosphamide, dexamethasone (PCD) versus pomalidomide and dexamethason...
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study evaluates the real-world efficacy and safety of two CAR T-cell therapies, idecabtagene vicleucel (ide-cel) an...
Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study analyzed early mortality in multiple myeloma using data from the J-CHARGE-MM database, identifying that nearl...
The challenge of non-transplant eligible, newly diagnosed multiple myeloma.
- Post category:Hematologic Cancers
- Reading time:1 min read
This meta-analysis of randomized studies up to February 2025 evaluated first-line treatment strategies in newly-diagnose...